Tag: NYSEMKT:INO

Finance

Biotech Losers: Inovio Pharmaceuticals (NYSEMKT:INO), Oncomed Pharmaceuticals (NASDAQ:OMED), Enzymotec (NASDAQ:ENZY), Veracyte Inc (NASDAQ:VCYT)

Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) announced financial results for the quarter and year ended December 31, 2013. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -7.98% in last session and finished the day at $3.23. Traded volume was 10,401,414 million shares in the last session and the average volume of the stock remained 7.79 million shares. The beta of the stock remained 3.69. Inovio Pharmaceuticals Inc (NYSEMKT:INO) … Continue reading Biotech Losers: Inovio Pharmaceuticals (NYSEMKT:INO), Oncomed Pharmaceuticals (NASDAQ:OMED), Enzymotec (NASDAQ:ENZY), Veracyte Inc (NASDAQ:VCYT)

Kristen Barton
Finance

Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Inovio Pharmaceuticals Inc (NYSEMKT:INO) reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same periods in 2012. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -7.98% in last session and finished the day at $3.23. … Continue reading Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Colin Pettis
Finance

Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Inovio Pharmaceuticals Inc (NYSEMKT:INO) reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same periods in 2012. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -7.98% in last session and finished the day at $3.23. … Continue reading Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Jayne Crisman
Finance

Bearish Stocks: Himax Technologies (NASDAQ:HIMX), Inovio Pharmaceuticals (NYSEMKT:INO), MagneGas Corporation (NASDAQ:MNGA), Intellicheck Mobilisa (NYSEMKT:IDN)

Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) shares were hurt by yesterday’s announcement of a downgrade from BofA Merrill Lynch. HIMX represents almost 9% of Tiger Global’s portfolio. Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) stock performance was -11.36% in last session and finished the day at $11.86. Traded volume was 24,728,552 million shares in the last session and the average volume of the stock remained 7.66 million shares. … Continue reading Bearish Stocks: Himax Technologies (NASDAQ:HIMX), Inovio Pharmaceuticals (NYSEMKT:INO), MagneGas Corporation (NASDAQ:MNGA), Intellicheck Mobilisa (NYSEMKT:IDN)

Colin Pettis
Finance

Biotech Active Stocks: Celgene Corporation (NASDAQ:CELG), Arena Pharmaceuticals (NASDAQ:ARNA), Cell Therapeutics (NASDAQ:CTIC), Inovio Pharmaceuticals (NYSEMKT:INO)

U.S. health regulators on Friday approved a Celgene Corporation (NASDAQ:CELG) drug to treat psoriatic arthritis, a type of arthritis associated with the skin disease psoriasis that causes joint pain, stiffness and swelling. Celgene Corporation (NASDAQ:CELG) stock performance was -3.74% in last session and finished the day at $144.40. Traded volume was 9.50million shares in the last session and the average volume of the stock remained … Continue reading Biotech Active Stocks: Celgene Corporation (NASDAQ:CELG), Arena Pharmaceuticals (NASDAQ:ARNA), Cell Therapeutics (NASDAQ:CTIC), Inovio Pharmaceuticals (NYSEMKT:INO)

John Meady
Finance

Biotech Most Volatile: MannKind Corporation (NASDAQ:MNKD), Inovio Pharmaceuticals (NYSEMKT:INO), Galena Biopharma (NASDAQ:GALE), Geron Corporation (NASDAQ:GERN)

MannKind Corporation (NASDAQ:MNKD) on Feb. 18 reported financial results for the fourth quarter and full year ended December 31, 2013. The net loss applicable to common stockholders for fiscal year 2013 was $(191.5) million, or $(0.64) per share based on 299.6 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $(169.4) million, or $(0.94) per share based on 180.9 … Continue reading Biotech Most Volatile: MannKind Corporation (NASDAQ:MNKD), Inovio Pharmaceuticals (NYSEMKT:INO), Galena Biopharma (NASDAQ:GALE), Geron Corporation (NASDAQ:GERN)

Chris Lewis